Lupin Diagnostics Limited (LDL), a fully owned subsidiary of global pharmaceutical leader Lupin Limited, has reached a significant milestone in its journey toward becoming a leader in diagnostic services. The company has achieved 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation for all its greenfield laboratories. This accreditation is a testament to LDL’s unwavering commitment to delivering accurate, reliable, and high-quality diagnostic services across India.
The NABL accreditation is one of the most respected standards in the healthcare industry. It ensures that diagnostic labs adhere to stringent quality assurance, testing protocols, and patient safety norms, aligning them with international standards. By receiving this accreditation, LDL’s greenfield labs have proven their ability to consistently meet these high standards in testing and calibration, offering patients the confidence they deserve when undergoing medical testing.
At present, LDL operates 27 greenfield labs spread across various locations in India, serving thousands of patients by providing timely diagnostic results. These labs are equipped with state-of-the-art technology and staffed with experienced professionals committed to accuracy and precision. The NABL accreditation further bolsters LDL’s reputation as a trusted diagnostic partner, ensuring that all tests conducted are performed under the most stringent conditions, reducing the risk of errors and enhancing the quality of service.
CEO Ravindra Kumar of Lupin Diagnostics highlighted that this achievement is a reflection of the company’s core values and its commitment to patient care. He stated, “This accreditation is a huge leap forward in ensuring that our patients receive accurate results and the highest quality of diagnostic care. We believe that a healthier nation begins with reliable diagnostics, and we will continue to innovate and improve to support better healthcare outcomes.”
Lupin Diagnostics’ newly accredited labs will continue to play a vital role in meeting the growing demand for high-quality diagnostic testing in India. The company’s commitment to excellence in diagnostics is poised to enhance the overall healthcare experience for its patients, ensuring that they receive accurate test results quickly and efficiently.
With this achievement, Lupin Diagnostics strengthens its position in the competitive Indian diagnostic market. The company aims to further expand its network of greenfield labs, providing access to internationally recognized testing services in more regions. This expansion will not only benefit patients but also contribute to improving healthcare standards in India.
Through this accomplishment, Lupin Diagnostics reinforces its role as a leader in the Indian healthcare sector, committed to quality, innovation, and patient-centric care.